175 related articles for article (PubMed ID: 15050889)
1. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy.
Delmas PD; Seeman E
Bone; 2004 Apr; 34(4):599-604. PubMed ID: 15050889
[TBL] [Abstract][Full Text] [Related]
2. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses.
Delmas PD; Li Z; Cooper C
J Bone Miner Res; 2004 Feb; 19(2):330-7. PubMed ID: 14969404
[TBL] [Abstract][Full Text] [Related]
3. Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture?
Li Z; Chines AA; Meredith MP
J Musculoskelet Neuronal Interact; 2004 Mar; 4(1):64-74. PubMed ID: 15615079
[TBL] [Abstract][Full Text] [Related]
4. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
Hochberg MC; Greenspan S; Wasnich RD; Miller P; Thompson DE; Ross PD
J Clin Endocrinol Metab; 2002 Apr; 87(4):1586-92. PubMed ID: 11932287
[TBL] [Abstract][Full Text] [Related]
5. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
Seeman E
Bone; 2007 Sep; 41(3):308-17. PubMed ID: 17644058
[TBL] [Abstract][Full Text] [Related]
6. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis.
Jamal SA; Hayden JA; Beyene J
Am J Kidney Dis; 2007 May; 49(5):674-81. PubMed ID: 17472850
[TBL] [Abstract][Full Text] [Related]
7. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
8. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women.
Garnero P; Delmas PD
J Musculoskelet Neuronal Interact; 2004 Mar; 4(1):50-63. PubMed ID: 15615078
[TBL] [Abstract][Full Text] [Related]
9. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
Bonnick SL; Shulman L
Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
11. Low width of tubular bones is associated with increased risk of fragility fracture in elderly men--the MINOS study.
Szulc P; Munoz F; Duboeuf F; Marchand F; Delmas PD
Bone; 2006 Apr; 38(4):595-602. PubMed ID: 16249130
[TBL] [Abstract][Full Text] [Related]
12. Emerging concepts in osteoporosis and bone strength.
Rubin CD
Curr Med Res Opin; 2005 Jul; 21(7):1049-56. PubMed ID: 16004672
[TBL] [Abstract][Full Text] [Related]
13. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
14. Disc space narrowing as a new risk factor for vertebral fracture: the OFELY study.
Sornay-Rendu E; Allard C; Munoz F; Duboeuf F; Delmas PD
Arthritis Rheum; 2006 Apr; 54(4):1262-9. PubMed ID: 16572461
[TBL] [Abstract][Full Text] [Related]
15. Evolution of bone mineral density after percutaneous kyphoplasty in fresh osteoporotic vertebral body fractures and adjacent vertebrae along with sagittal spine alignment.
Korovessis P; Zacharatos S; Repantis T; Michael A; Karachalios D
J Spinal Disord Tech; 2008 Jun; 21(4):293-8. PubMed ID: 18525491
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
18. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
19. Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study.
Kaptoge S; Benevolenskaya LI; Bhalla AK; Cannata JB; Boonen S; Falch JA; Felsenberg D; Finn JD; Nuti R; Hoszowski K; Lorenc R; Miazgowski T; Jajic I; Lyritis G; Masaryk P; Naves-Diaz M; Poor G; Reid DM; Scheidt-Nave C; Stepan JJ; Todd CJ; Weber K; Woolf AD; Roy DK; Lunt M; Pye SR; O'neill TW; Silman AJ; Reeve J
Bone; 2005 Mar; 36(3):387-98. PubMed ID: 15777673
[TBL] [Abstract][Full Text] [Related]
20. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases.
Kumagai S; Kawano S; Atsumi T; Inokuma S; Okada Y; Kanai Y; Kaburaki J; Kameda H; Suwa A; Hagiyama H; Hirohata S; Makino H; Hashimoto H
J Rheumatol; 2005 May; 32(5):863-9. PubMed ID: 15868623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
